FDA 483 - Cytovance Biologics Inc. - June 08, 2026
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Cytovance Biologics Inc. in Oklahoma City, OK, an API manufacturer, revealed significant deficiencies across multiple systems. The firm was cited for repeat observations concerning facility maintenance and equipment qualification, alongside failures in cleaning validation, deviation investigations, raw material testing justification, and labeling procedures. These issues indicate a lack of adequate control over critical manufacturing processes and quality systems.
ID · 7c829e5f-6b20-41d1-8204-1ec5de895194